Clinical Trial Update: Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of FOLFIRI plus cetuximab and IMO-2055 in colorectal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• IMO-2055

Snippet

Sponsor: EMD Serono | Conditions: Colorectal Cancer | Phase 1 | Status: TERMINATED